Correction of osteopetrosis in the neonate

HSC mobilization TCIRG1 gene conditioning gene therapy hematopoietic stem cells lentiviral vector osteoclast osteopetrosis

Journal

Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782

Informations de publication

Date de publication:
2024
Historique:
received: 17 06 2024
accepted: 05 08 2024
medline: 24 9 2024
pubmed: 24 9 2024
entrez: 24 9 2024
Statut: epublish

Résumé

Autosomal recessive osteopetrosis (ARO) is a rare genetic disease, characterized by increased bone density due to defective osteoclast function. Most of the cases are due to The First, we showed that lentiviral vector GT can revert the osteopetrotic bone phenotype, allowing long-term survival and reducing extramedullary haematopoiesis. Then, we demonstrated that plerixafor-induced mobilization can further increase the high number of HSPCs circulating in peripheral blood, facilitating the collection of adequate numbers of cells for therapeutic purposes. Finally, pre-transplant non-genotoxic conditioning allowed the stable engraftment of HSPCs, albeit at lower level than conventional total body irradiation, and led to long-term survival and correction of bone phenotype, in the absence of acute toxicity. These results will pave the way to the implementation of an effective GT protocol, reducing the transplant-related complication risks in the very young and severely affected ARO patients.

Identifiants

pubmed: 39314524
doi: 10.3389/fendo.2024.1450349
pmc: PMC11416974
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1450349

Informations de copyright

Copyright © 2024 Penna, Zecchillo, Di Verniere, Fontana, Iannello, Palagano, Mantero, Cappelleri, Rizzoli, Santi, Crisafulli, Filibian, Forlino, Basso-Ricci, Scala, Scanziani, Schinke, Ficara, Sobacchi, Villa and Capo.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.

Auteurs

Sara Penna (S)

San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, Milan, Italy.

Alessandra Zecchillo (A)

San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, Milan, Italy.
Translational and Molecular Medicine (DIMET), University of Milano Bicocca, Milan, Italy.

Martina Di Verniere (M)

San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, Milan, Italy.

Elena Fontana (E)

Milan Unit, Istituto di Ricerca Genetica e Biomedica, Consiglio Nazionale delle Ricerche, Milan, Italy.
Humanitas Research Hospital IRCCS, Rozzano, MI, Italy.

Valeria Iannello (V)

San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, Milan, Italy.
Vita-Salute San Raffaele University, Milan, Italy.

Eleonora Palagano (E)

Humanitas Research Hospital IRCCS, Rozzano, MI, Italy.
Florence Unit, Istituto di Bioscienze e Biorisorse, Consiglio Nazionale delle Ricerche, Sesto Fiorentino, Italy.

Stefano Mantero (S)

Milan Unit, Istituto di Ricerca Genetica e Biomedica, Consiglio Nazionale delle Ricerche, Milan, Italy.
Humanitas Research Hospital IRCCS, Rozzano, MI, Italy.

Andrea Cappelleri (A)

Mouse and Animal Pathology Laboratory, UniMi Foundation, Milan, Italy.
Department of Veterinary Medicine and Animal Sciences, University of Milan, Lodi, Italy.

Elena Rizzoli (E)

San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, Milan, Italy.
Vita-Salute San Raffaele University, Milan, Italy.

Ludovica Santi (L)

San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, Milan, Italy.

Laura Crisafulli (L)

Milan Unit, Istituto di Ricerca Genetica e Biomedica, Consiglio Nazionale delle Ricerche, Milan, Italy.
Humanitas Research Hospital IRCCS, Rozzano, MI, Italy.

Marta Filibian (M)

Biomedical Imaging Laboratory, Centro Grandi Strumenti, University of Pavia, Pavia, Italy.

Antonella Forlino (A)

Department of Molecular Medicine, Biochemistry Unit, University of Pavia, Pavia, Italy.

Luca Basso-Ricci (L)

San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, Milan, Italy.

Serena Scala (S)

San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, Milan, Italy.

Eugenio Scanziani (E)

Mouse and Animal Pathology Laboratory, UniMi Foundation, Milan, Italy.
Department of Veterinary Medicine and Animal Sciences, University of Milan, Lodi, Italy.

Thorsten Schinke (T)

Department of Osteology and Biomechanics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Francesca Ficara (F)

Milan Unit, Istituto di Ricerca Genetica e Biomedica, Consiglio Nazionale delle Ricerche, Milan, Italy.
Humanitas Research Hospital IRCCS, Rozzano, MI, Italy.

Cristina Sobacchi (C)

Milan Unit, Istituto di Ricerca Genetica e Biomedica, Consiglio Nazionale delle Ricerche, Milan, Italy.
Humanitas Research Hospital IRCCS, Rozzano, MI, Italy.

Anna Villa (A)

San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, Milan, Italy.
Milan Unit, Istituto di Ricerca Genetica e Biomedica, Consiglio Nazionale delle Ricerche, Milan, Italy.

Valentina Capo (V)

San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute, Milan, Italy.
Milan Unit, Istituto di Ricerca Genetica e Biomedica, Consiglio Nazionale delle Ricerche, Milan, Italy.

Classifications MeSH